Gary E Striker

Title: Gary E. Striker: Innovator in Lysosomal Disorder Therapies

Introduction

Gary E. Striker is a notable inventor based in New York, NY (US). He has made significant contributions to the field of medicine, particularly in the treatment of lysosomal disorders. With a total of 2 patents, his work has the potential to impact many lives.

Latest Patents

Striker's latest patents include innovative therapies aimed at treating mucopolysaccharidoses and other lysosomal disorders. One patent focuses on methods of treating subjects with lysosomal disorders by administering an agent for enzyme replacement therapy alongside an agent for anti-TNF-α therapy. This invention also explores the use of pentosan polysulfate therapy and substrate reduction therapy in conjunction with anti-TNF-α therapy. Another significant patent involves the inhibition of TNF-α induced activation of NFKB by pentosan polysulfate, which has applications in treating diseases such as diabetes, inflammation, and atherosclerosis. These compositions are effective in reducing matrix metalloproteinases (MMPs).

Career Highlights

Throughout his career, Gary E. Striker has worked with prestigious institutions such as the Icahn School of Medicine at Mount Sinai and Mount Sinai School of Medicine. His research has been pivotal in advancing therapeutic options for patients suffering from lysosomal disorders.

Collaborations

Striker has collaborated with esteemed colleagues, including Helen Vlassara and Edward Howard Schuchman. Their combined expertise has contributed to the development of innovative treatment methodologies.

Conclusion

Gary E. Striker's contributions to the field of medicine, particularly in lysosomal disorder therapies, highlight his role as a significant inventor. His patents reflect a commitment to improving patient outcomes through innovative treatments.